3,3',4',5,7-Pentamethylquercetin reduces angiotensin II-induced cardiac hypertrophy and apoptosis in rats.

Abstract

Quercetin has been shown to possess beneficial pharmacological properties in treatment of heart disease, but lack of stability and bioavailability limits its clinical use. In this study, we investigated for the first time the effect of a methylated form of quercetin, 3,3',4',5,7-pentamethylquercetin (PMQ), on myocardial protection in rats. Angiotensin II was delivered to Sprague-Dawley rats subcutaneously, while PMQ (5 mg/kg) was administered by oral gavage; blood pressure was monitored daily. The production of NADPH oxidase was measured, and cardiac hypertrophy and apoptosis were detected. The results revealed that PMQ could downregulate the expression of the NADPH oxidase gene and reduce angiotensin II- induced cardiac hypertrophy and apoptosis in rats. Therefore, we believe that PMQ showed beneficial effects on myocardium in angiotensin II-administered rats, and its potential to be used for treatment of cardiovascular disease deserves further attention.

• Authors: Zhangfan Mao, Yuanxin Liang, Xinling Du, Zongquan Sun
• Journal: Canadian journal of physiology and pharmacology (Can J Physiol Pharmacol) Vol. 87 Issue 9 Pg. 720-8 (Sep 2009) ISSN: 1205-7541 [Electronic] Canada
• PMID: 19794523 (Publication Type: Journal Article)

Chemical References

• 3,3',4',5,7-pentamethylquercetin
• Cardiotonic Agents
• Angiotensin II
• Quercetin
• NADPH Oxidases

Topics

• Angiotensin II (adverse effects)
• Animals
• Apoptosis (drug effects)
• Cardiomegaly (chemically induced, enzymology, pathology, prevention & control)
• Cardiotonic Agents (administration & dosage, pharmacology, therapeutic use)
• Down-Regulation
• Gene Expression (drug effects)
• Male
• Molecular Structure
• NADPH Oxidases (antagonists & inhibitors, genetics)
• Quercetin (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
• Rats
• Rats, Sprague-Dawley